The Real-World Outcomes of Treating Polycythemia Vera: Physician Adherence to Treatment Guidelines

Polycythemia Vera (PV) is a BCR-ABL negative myeloproliferative neoplasm characterized by the proliferation of red blood cells, although white blood cells and platelets are often also elevated. [1] Mutations of Janus Kinase 2 (JAK2), particularly JAK2V617F, are present in 98% of PV patients.[2] The natural history of PV includes progression to myelofibrosis (MF), myelodysplastic syndrome or acute myeloid leukemia (AML) at a rate of 1.3 progressions per 100 patient-years.[3] Untreated life expectancy is 6 to 18 months.[1] Lifespan is extended with treatment, although mortality is still about 1.6 times higher than age-matched controls.[4],[5]
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research